|
Time to first-line (1L) therapy discontinuation in metastatic melanoma (MM). |
|
|
Honoraria - Intellisphere, LLC |
Consulting or Advisory Role - 7 Hills Pharma; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Merck; Novartis |
Research Funding - Abbvie; Boston Biomedical; Bristol-Myers Squibb; Celldex; Corvus Pharmaceuticals; Delcath Systems; Five Prime Therapeutics; Genentech/Roche; Immunocore; Incyte; MedImmune; Merck; Pharmacyclics |
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Bristol-Myers Squibb |
|
|
|
Stock and Other Ownership Interests - Bluebird Bio; Exelixis (I); Juno Therapeutics; Mannkind; Novartis; Provectus; Provectus |
|
|
Employment - Analysis Group |
Research Funding - Novartis (Inst) |
|
|
|
Research Funding - Novartis; Novartis |
|
|
Employment - Analysis Group |
Research Funding - Novartis (Inst) |
|
|
Employment - Analysis Group |
|
|
No Relationships to Disclose |